View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2019	Mar. 23, 2020	Jun. 30, 2019
Document And Entity Information
Entity Registrant Name	IMAC Holdings, Inc.
Entity Central Index Key	0001729944
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 23,500,000
Entity Common Stock, Shares Outstanding		9,835,960
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash	$ 373,689	$ 194,316
Accounts receivable, net	1,258,325	303,630
Deferred compensation, current portion	312,258
Other assets	633,303	170,163
Total current assets	2,577,575	668,109
Property and equipment, net	3,692,009	3,333,638
Other assets:
Goodwill	2,040,696	2,042,125
Intangible assets, net	7,169,072	4,257,434
Deferred IPO costs		335,318
Deferred equity costs	170,274
Deferred compensation, net of current portion	549,563
Security deposits	499,488	438,163
Right of use asset	3,719,401
Total other assets	14,148,494	7,073,040
Total assets	20,418,078	11,074,787
Current liabilities:
Accounts payable and accrued expenses	2,909,666	1,261,582
Acquisition liabilities		7,259,208
Patient deposits	189,691	454,380
Notes payable, current portion	1,422,554	4,459,302
Finance lease obligation, net of current portion	17,473	16,740
Lines of credit	79,961	379,961
Liability to issue common stock, current portion	421,044
Operating lease liability, current portion	1,025,247
Total current liabilities	6,065,636	13,831,173
Long-term liabilities:
Notes payable, net of current portion	2,109,065	317,291
Finance lease obligation, net of current portion	66,565	84,038
Deferred rent		197,991
Lease incentive obligation		576,454
Liability to issue common stock, net of current portion	578,866
Operating lease liability, net of current portion	3,660,654
Total liabilities	12,480,786	15,006,947
Stockholders' equity (deficit):
Preferred stock - $0.001 par value, 5,000,000 authorized, nil issued and outstanding at December 31, 2019 and 2018
Common stock; $0.001 par value, 30,000,000 authorized, 8,913,258 and 4,533,623 shares issued and outstanding at December 31, 2019 and 2018, respectively	8,907	4,534
Additional paid-in capital	20,050,634	1,233,966
Accumulated deficit	(10,042,050)	(3,544,820)
Non-controlling interest	(2,080,199)	(1,625,840)
Total stockholders' equity (deficit)	7,937,292	(3,932,160)
Total liabilities and stockholders' equity	$ 20,418,078	$ 11,074,787

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	8,913,258	4,533,623
Common stock, shares outstanding	8,913,258	4,533,623

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Total patient revenue, net	$ 15,100,708	$ 6,637,071
Total revenue	15,126,026	6,701,071
Operating expenses:
Patient expenses	2,540,323	933,907
Salaries and benefits	10,523,409	4,730,035
Share-based compensation	392,217	14,998
Advertising and marketing	1,238,352	859,191
General and administrative	5,064,437	3,063,270
Depreciation and amortization	1,552,919	651,066
Total operating expenses	21,311,657	10,252,467
Operating loss	(6,185,631)	(3,551,396)
Other income (expense):
Interest income	7,794	7,541
Other income (expense)	(16,132)	18,356
Beneficial conversion interest expense	(639,159)
Gain on sale of assets	140,074
Interest expense	(258,535)	(153,824)
Total other income (expenses)	(765,958)	(127,927)
Loss before equity in earnings (loss) of non-consolidated affiliate	(6,951,589)	(3,679,323)
Equity in earnings (loss) of non-consolidated affiliate		(105,550)
Net loss before income taxes	(6,951,589)	(3,784,873)
Income taxes
Net loss	(6,951,589)	(3,784,873)
Net loss attributable to non-controlling interest	454,359	731,130
Net loss attributable to IMAC Holdings, Inc.	$ (6,497,230)	$ (3,053,743)
Net loss per share attributable to common stockholders Basic and diluted	$ (0.84)	$ (0.47)
Weighted average common shares outstanding Basic and diluted	7,753,642	4,533,623
Patient Revenues [Member]
Total patient revenue, net		$ 16,135,967
Contractual Adjustments [Member]
Total patient revenue, net		(9,498,896)
Management Fees [Member]
Total revenue	$ 25,318	$ 64,000

Consolidated Statement of Stockholders' Equity (Deficit) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Non-Controlling Interest [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017	$ 6,583	$ 1,233,966	$ (575,994)	$ (491,077)	$ 173,478
Balance, shares at Dec. 31, 2017	6,582,737
Net loss			(730,704)	(3,053,743)	(3,784,873)
Purchase of non-controlling interest			(319,142)		(319,142)
Reverse stock split	$ (2,049)				(2,049)
Reverse stock split, shares	(2,049,114)
Balance at Dec. 31, 2018	$ 4,534	1,233,966	(1,625,840)	(3,544,820)	(3,932,160)
Balance, shares at Dec. 31, 2018	4,533,623
Common stock issued for initial public offering proceeds, net of related fees	$ 850	3,503,314			3,504,164
Common stock issued for initial public offering proceeds, net of related fees, shares	850,000
Issuance of common stock in connection with convertible notes	$ 449	2,245,636			2,246,085
Issuance of common stock in connection with convertible notes, shares	449,217
Issuance of common stock in connection with acquisitions	$ 2,412	11,320,234			11,322,646
Issuance of common stock in connection with acquisitions, shares	2,412,489
Exercise of warrants	$ 72	357,273			357,345
Exercise of warrants, shares	71,469
Issuance of employee stock options		79,104			79,104
Issuance of common stock	$ 590	1,311,107			1,311,697
Issuance of common stock, shares	596,460
Net loss			(454,359)	(6,497,230)	(6,951,589)
Balance at Dec. 31, 2019	$ 8,907	$ 20,050,634	$ (2,080,199)	$ (10,042,050)	$ 7,937,292
Balance, shares at Dec. 31, 2019	8,913,258

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net loss	$ (6,951,589)	$ (3,784,873)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,552,919	651,066
Beneficial conversion interest expense	639,159
Share based compensation	392,217	14,998
Deferred rent		133,238
Equity in (earnings) loss of non-consolidated affiliate		(105,550)
(Increase) decrease in operating assets:
Accounts receivable, net	(412,805)	(170,235)
Due from related parties		(95,501)
Other assets	(271,654)	(70,038)
Security deposits	(111,400)	(410,335)
Increase (decrease) in operating liabilities:
Accounts payable and accrued expenses	1,359,099	1,204,417
Patient deposits	(264,689)	323,474
Lease incentive obligation		516,026
Net cash used in operating activities	(4,068,743)	(1,808,310)
Cash flows from investing activities:
Purchase of property and equipment	(1,200,216)	(1,579,842)
Cash paid for acquisitions		(23,931)
Proceeds from sale of fixed assets	147,096
Net cash used in investing activities	(1,053,120)	(1,603,773)
Cash flows from financing activities:
Proceeds from initial public offering, net of related fees	3,839,482
Proceeds from warrants exercised	357,345
Proceeds from issuance of common stock	1,311,697
Proceeds from notes payable	212,800	3,998,195
Payments on notes payable	(123,348)	(193,625)
Proceeds from line of credit	20,000	175,000
Payments on line of credit	(300,000)	(140,000)
Payments on finance lease obligation	(16,740)	(25,642)
Deferred IPO costs		(335,318)
Net cash provided by financing activities	5,301,236	3,478,610
Net increase in cash	179,373	66,527
Cash, beginning of period	194,316	127,789
Cash, end of period	373,689	194,316
Supplemental cash flow information:
Interest paid	97,147	153,824
Taxes paid	18,533
Non Cash Financing and Investing:
Business acquisition via stock issuance	$ 3,771,978	$ 7,259,208

Description of Business

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Description of Business

Note 1 – Description of Business

IMAC Holdings, Inc. and its affiliates (collectively, the “Company”) provide orthopedic therapies through its chain of IMAC Regeneration Centers. Through its consolidated and equity owned entities, its outpatient medical clinics provide conservative, non-invasive medical treatments to help patients with back pain, knee pain, joint pain, ligament and tendon damage, and other related soft tissue conditions. The Company has opened two (2) medical clinics located in Tennessee and opened or acquired through Management Service Agreements thirteen (13) medical clinics located in Kentucky, Missouri and Illinois at December 31, 2019. The Company has partnered with several well-known sports stars such as Ozzie Smith, David Price, Tony Delk, and Mike Ditka in opening its medical clinics, with a focus around treating sports injuries.

Effective June 1, 2018, the Company converted from IMAC Holdings, LLC a Kentucky limited liability company to IMAC Holdings, Inc. a Delaware Corporation, followed by a reverse stock split in February 2019. These accounting changes have been given retrospective treatment in the consolidated financial statements.

During February 2019, the Company completed an initial public offering (“IPO”) of securities. See Note 12 – Stockholder’s Equity.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying consolidated financial statements have been prepared in accordance with Generally Accepted Accounting Principles (“GAAP”) in the United States of America (“U.S.”) as promulgated by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”).

The accompanying consolidated financial statements include the accounts of IMAC Holdings, Inc. (“IMAC Holdings”) and the following entities which are consolidated due to direct ownership of a controlling voting interest or other rights granted to us as the sole general partner or managing member of the entity: IMAC Management Services, LLC (“IMAC Management”), IMAC Regeneration Management, LLC (“IMAC Texas”), IMAC Regeneration Management of Nashville, LLC (“IMAC Nashville”) and IMAC Management of Illinois, LLC (“IMAC Illinois”); the following entity which is consolidated with IMAC Regeneration Management of Nashville, LLC due to control by contract: IMAC Regeneration Center of Nashville, PC (“IMAC Nashville PC”); and the following which prior to June 1, 2018 was held as a minority interest, IMAC Regeneration Center of St. Louis, LLC (“IMAC St. Louis”).

In June 2018, the Company consummated certain transactions resulting in the acquisition of the outstanding equity interests in IMAC St. Louis and Clinic Management Associates of KY, LLC (“CMA of KY”), an entity which consolidates Integrated Medical and Chiropractic Regeneration Center, PSC (“IMAC Kentucky”) due to control by contract. These entities are included in the consolidated financial statements from the date of acquisition.

In August 2018, the Company acquired 100% of Advantage Hand Therapy and Orthopedic Rehabilitation, LLC (“Advantage Therapy”) and 70% of BioFirma LLC (“BioFirma”). Both companies are consolidated due to direct ownership of a controlling voting interest or other rights granted to us as the sole general partner or managing member of the entity. Substantially all of the assets of BioFirma were sold effective December 31, 2019.

In April 2019, the Company consummated certain transactions resulting in the acquisition of the outstanding equity interest in ISDI Holdings II, Inc., an Illinois corporation (“ISDI Holdings II”), and PHR Holdings, Inc., an Illinois corporation (“PHR Holdings”), entities which consolidate the results of Progressive Health and Rehabilitation, Ltd (“Progressive”) and Illinois Spine and Disc Institute, Ltd (“ISDI”) due to control by contract. These entities are included in the consolidated financial statements from the date of acquisition.

All significant intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses at the date and for the periods that the consolidated financial statements are prepared. On an ongoing basis, the Company evaluates its estimates, including those related to insurance adjustments and provisions for doubtful accounts. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could materially differ from those estimates.

Revenue Recognition

The Company’s patient service revenue is derived from non-surgical procedures performed at our outpatient medical clinics and patient visits to physicians. The fees for such services are billed either to the patient or a third- party payer, including Medicare. The Company recognizes service revenues based upon the estimated amounts the Company expects to be entitled to receive from patients and third-party payers. Estimates of contractual adjustments are based upon the payment terms specified in the related contractual agreements. The Company also records estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record these revenues at the estimated amounts expected to be collected.

Other management service fees are derived from management services where the Company provides billings and collections support to the clinics and where management services are provided based on state specific regulations known as the corporate practice of medicine (“CPM”). Under the CPM, a business corporation is precluded from practicing medicine or employing a physician to provide professional medical services. In these circumstances, the Company provides all administrative support to the physician-owned PC through an LLC. The PC is consolidated due to control by contract (an “MSA” – Management Services Agreement). The fees we derive from these management arrangements are either based on a predetermined percentage of the revenue of each clinic or a percentage mark up on the costs of the LLC. The company recognize other management service revenue in the period in which services are rendered. These revenues are earned by IMAC Nashville, IMAC Management and IMAC Illinois and are eliminated in consolidation to the extent owned.

The Company’s patient revenue consisted of the following as of December 31, 2019 and 2018:

	2019			2018

Patient revenues	$	32,756,644		$	16,135,967
Contractual adjustments		(17,655,936	)		(9,498,896	)
Patient revenue, net	$	15,100,708		$	6,637,071

Patient Deposits

Patient deposits are derived from patient payments in advance of services delivered. Our service lines include traditional and regenerative medicine. Regenerative medicine procedures are rarely paid by insurance carriers; therefore, the Company typically requires up-front payment from the patient for regenerative services and any co-pays and deductibles as required by the patient specific insurance carrier. For some patients, credit is provided through an outside vendor. In this case, the Company is paid from the credit card company and the risk is transferred to the credit card company for collection from the patient. These funds are accounted for as patient deposits until the procedures are performed at which point the patient deposit is recognized as patient service revenue.

Fair Value of Financial Instruments

The carrying amount of accounts receivable, accounts payable and acquisition liabilities approximate their respective fair values due to the short- term nature. The carrying amount of the line of credit and note payable approximates fair values due to their market interest rates. Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and accounts receivable.

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. The Company had no cash equivalents at December 31, 2019 and 2018.

Accounts Receivable

Accounts receivable primarily consists of amounts due from third-party payers (non-governmental), governmental payers and private pay patients and is recorded net of allowances for doubtful accounts and contractual discounts. The Company’s ability to collect outstanding receivables is critical to its results of operations and cash flows. Accordingly, accounts receivable reported in the Company’s consolidated financial statements is recorded at the net amount expected to be received. The Company’s primary collection risks are (i) the risk of overestimation of net revenues at the time of billing that may result in the Company receiving less than the recorded receivable, (ii) the risk of non-payment as a result of commercial insurance companies’ denial of claims, (iii) the risk that patients will fail to remit insurance payments to the Company when the commercial insurance company pays out-of-network claims directly to the patient, (iv) resource and capacity constraints that may prevent the Company from handling the volume of billing and collection issues in a timely manner, (v) the risk that patients do not pay the Company for their self-pay balances (including co-pays, deductibles and any portion of the claim not covered by insurance) and (vi) the risk of non-payment from uninsured patients.

The Company’s accounts receivable from third-party payers are recorded net of estimated contractual adjustments and allowances from third-party payers, which are estimated based on the historical trend of the Company’s facilities’ cash collections and contractual write- offs, accounts receivable aging, established fee schedules, relationships with payers and procedure statistics. While changes in estimated reimbursement from third-party payers remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on the Company’s financial condition or results of operations. The Company’s collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The operating systems used to manage the Company’s patient accounts provide for an aging schedule in 30-day increments, by payer, physician and patient. The Company analyzes accounts receivable at each of the facilities to ensure the proper collection and aged category. The operating systems generate reports that assist in the collection efforts by prioritizing patient accounts. Collection efforts include direct contact with insurance carriers or patients and written correspondence.

Allowance for Doubtful Accounts, Contractual and Other Discounts

Management estimates the allowance for contractual and other discounts based on its historical collection experience and contracted relationship with the payers. The services authorized and provided and related reimbursement are often subject to interpretation and negotiation that could result in payments that differ from the Company’s estimates. The Company’s allowance for doubtful accounts is based on historical experience, but management also takes into consideration the age of accounts, creditworthiness and current economic trends when evaluating the adequacy of the allowance for doubtful accounts. An account may be written-off only after the Company has pursued collection efforts or otherwise determines an account to be uncollectible. Uncollectible balances are written-off against the allowance. Recoveries of previously written-off balances are credited to income when the recoveries are made.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation. Additions and improvements to property and equipment are capitalized at cost. Depreciation of owned assets and amortization of leasehold improvements are computed using the straight-line method over the shorter of the estimated useful lives of the related assets or the lease term. The cost of assets sold or retired, and the related accumulated depreciation are removed from the accounts and any resulting gains or losses are reflected in other income (expense) for the year. Expenditures for maintenance and repairs are charged to expense as incurred.

Intangible Assets

The Company capitalizes the fair value of intangible assets acquired in business combinations. Intangible assets are amortized on a straight-line basis over their estimated economic useful lives, generally the contract term. The Company performs valuations of assets acquired and liabilities assumed on each acquisition accounted for as a business combination and allocates the purchase price of each acquired business to its respective net tangible and intangible assets. Acquired intangible assets include trade names, non-compete agreements, customer relationships and contractual agreements.

Goodwill

Our goodwill represents the excess of the purchase price over the fair value of the net identifiable assets acquired in business combinations. The goodwill generated from the business combinations is primarily related to the value placed on the employee workforce and expected synergies. Judgment is involved in determining if an indicator or change in circumstances relating to impairment has occurred. Such changes may include, among others, a significant decline in expected future cash flows, a significant adverse change in the business climate, and unforeseen competition. There was no goodwill impairment for the years presented.

The Company tests goodwill for impairment on an annual basis, or when events or circumstances indicate the fair value of a reporting unit is below its carrying value.

Long-Lived Assets

Long-lived assets such as property and equipment and intangible assets are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. There were no impairments of long-lived assets for the years presented.

Advertising and Marketing

The Company uses advertising and marketing to promote its services. Advertising and marketing costs are expensed as incurred. Advertising and marketing expense was $1,238,352 and $859,191 for the years ended December 31, 2019 and 2018, respectively.

Net Loss Per Share

Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of the conversion option embedded in convertible debt. The weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would have an anti-dilutive effect.

Income Taxes

IMAC Holdings was taxed as a partnership through May 31, 2018. As a result, income tax liabilities were passed through to the individual members. Accordingly, no provision for income taxes were reflected in the consolidated financial statements for periods prior to May 31, 2018, at which time the Company converted from a limited liability company to a Delaware corporation. Subsequent to the Company converting to a Delaware corporation, IMAC Nashville, IMAC Texas, IMAC St. Louis continued as single-member limited liability companies that are disregarded entities for tax purposes and do not file separate returns. Their activity is included as part of IMAC Holdings Inc. Advantage Therapy and IMAC Illinois are also disregarded entities for tax purposes. BioFirma is a limited liability company taxed as a partnership. Effective October 1, 2019, BioFirma became wholly owned by IMAC Holdings and is a disregarded entity for tax purposes. IMAC Management is a C-corporation and is included in the consolidated return of IMAC Holdings as a subsidiary.

Any future benefit arising from losses have been offset by a valuation allowance. Accordingly, no provision for income taxes is reflected in the consolidated financial statements. The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. Interest and penalties related to income tax matters, if any, would be recognized as a component of income tax expense. At December 31, 2019 and 2018, the Company had no liabilities for uncertain tax positions. The Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. Currently, the tax years subsequent to 2017 are open and subject to examination by the taxing authorities.

Recently Adopted Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, “Leases” which, for operating leases, requires a lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in its balance sheet. The standard also requires a lessee to recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term, on a generally straight-line basis. We adopted ASU 2016-02 on January 1, 2019. We recognized a right of use asset and a related obligation on our consolidated financial statements.

Recently Issued Accounting Pronouncements

In January 2017, the Financial Accounting Standards Board (“FASB”) issued ASU 2017-04 “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”. This update simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. Under this updated standard, an entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, but the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity also should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if any. This guidance is effective prospectively and is effective for interim and annual periods beginning after December 15, 2019 with early adoption permitted. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.

Capital Requirements, Liquidity and Going Concern Considerations

12 Months Ended

Dec. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Capital Requirements, Liquidity and Going Concern Considerations

Note 3 – Capital Requirements, Liquidity and Going Concern Considerations

The Company’s consolidated financial statements are prepared in accordance with GAAP including the assumption of a going concern basis, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, as shown in the accompanying consolidated financial statements, the Company has sustained substantial losses from operations since inception and had a deficiency in working capital of approximately $3.5 million at December 31, 2019. The Company had a net loss of approximately $6.5 million at December 31, 2019, and used cash in operations of approximately $4.1 million for the year ended December 31, 2019. The Company expects to continue to incur significant expenditures to develop and expand its owned and managed outpatient medical clinics.

Management recognizes that the Company must obtain additional resources to successfully integrate its acquired and managed clinics and implement its business plans. Through December 31, 2019, the Company has received funding in the form of indebtedness and from the sale of common stock and warrants. Management plans to continue to raise funds and/or refinance our indebtedness to support our operations in 2020 and beyond. However, no assurances can be given that we will be successful. If management is not able to timely and successfully raise additional capital and/or refinance indebtedness, the implementation of the Company’s business plan, financial condition and results of operations will be materially affected. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Concentration of Credit Risks

12 Months Ended

Dec. 31, 2019

Risks and Uncertainties [Abstract]

Concentration of Credit Risks

Note 4 – Concentration of Credit Risks

Cash

The Company maintains its cash in accounts at financial institutions, which may, at times, exceed federally-insured limits of $250,000. As of December 31, 2019, the Company had cash of approximately $0 in excess of federally insured limits.

Revenue and Accounts Receivable Concentration

As of December 31, 2019 and 2018, the Company had the following revenue and accounts receivable concentrations:

	2019						2018
	% of Revenue			% of Accounts Receivable			% of Revenue			% of Accounts Receivable

Patient payment		47	%		40	%		54	%		54	%
Medicare payment		27	%		26	%		20	%		20	%
Insurance payment		26	%		34	%		26	%		26	%

Accounts Receivable

12 Months Ended

Dec. 31, 2019

Receivables [Abstract]

Accounts Receivable

Note 5 – Accounts Receivable

Accounts receivable consisted of the following at December 31:

	2019			2018

Accounts receivable, net of contractual adjustments	$	1,285,228		$	314,185
Less: allowance for doubtful accounts		(26,903	)		(10,555	)
Accounts receivable, net	$	1,258,325		$	303,630

Business Acquisitions

12 Months Ended

Dec. 31, 2019

Business Combinations [Abstract]

Business Acquisitions

Note 6 – Business Acquisitions

During June 2018, the Company acquired CMA of Kentucky and IMAC St. Louis for aggregate consideration of approximately $6.1 million, which was paid in equity of the Company. The operating results of these two companies have been included in the Company’s consolidated financial statements from their dates of acquisition. The Company accounted for the transactions as business combinations and has allocated the purchase consideration to the net assets acquired based on estimated fair values.

In addition, during June 2018, the Company acquired the non-controlling interest held in a majority-owned subsidiary for $300,000, which was paid in equity of the Company.

During August 2018, the Company acquired Advantage Therapy and BioFirma for aggregate consideration of approximately $900,000, which was paid in cash and equity. The operating results of these two companies have been included in the Company’s consolidated financial statements from their dates of acquisition. The Company accounted for the transactions as business combinations and has allocated the purchase consideration to the net assets acquired based on estimated fair values. Substantially all of the assets of BioFirma were sold effective December 31, 2019.

During April 2019, the Company acquired ISDI Holdings II and PHR Holdings for aggregate consideration of approximately $4.1 million, which was paid in equity of the Company. The operating results of these companies have been included in the Company’s consolidated financial statements from the dates of acquisition. The Company accounted for the transactions as business combinations and has allocated the purchase consideration to the net assets acquired based on estimated fair values.

IMAC Kentucky

On June 29, 2018, IMAC Management completed a merger of CMA of Kentucky, which was merged into IMAC Management. Pursuant to this merger, IMAC Management has a long-term MSA to provide exclusive comprehensive management and related administrative services to IMAC Kentucky, an entity engaged in the practice of medicine through physicians and nurse practitioners. Under the IMAC Kentucky MSA, the Company receives service fees based on the cost of the services provided, plus a specified markup percentage, and a discretionary annual bonus.

The Company has included the consolidated financial results of IMAC Kentucky in the consolidated financial statements from the date of acquisition.

IMAC St. Louis

On June 1, 2018 the Company acquired the remaining 64% membership interest in IMAC St. Louis not already owned by it pursuant to a Unit Purchase Agreement, increasing the Company’s ownership to 100%. IMAC St. Louis operates two (2) Ozzie Smith Centers in Missouri. Pursuant to the terms of a Unit Purchase Agreement, the Company agreed to pay the current owners, upon the closing of the Company’s initial public offering, an amount equal to 1.05 times the total collections from payments at the IMAC St. Louis centers on account of regeneration-related services and associated products from the period from June 1, 2017 to May 31, 2018, or $1,490,632. The purchase consideration will be paid in the form of shares of our common stock based on the price per share of the Company’s common stock in the Company’s initial public offering. See Note 12 – Stockholders’ Equity.

The Company has included the financial results of IMAC St. Louis in the consolidated financial statements from June 1, 2018, the date of acquisition.

IMAC Nashville

Also, on June 1, 2018 the Company acquired the remaining 25% of the outstanding units of the limited liability company membership interests not already owned by the Company in IMAC Nashville for $300,000 and was paid in the form of shares of our common stock based on the price per share in the IPO. See Note 12 – Stockholders’ Equity.

Advantage Therapy

On August 1, 2018, the Company entered into an agreement to purchase all outstanding membership units of Advantage Therapy. The purchase price for the interests was equal to the dollar amount represented by 0.7 times the total collections from payments for service in the Company account from June 1, 2017 to May 31, 2018, or approximately $892,000, of which $870,000 and $22,000 and was paid in equity and cash, respectively. See Note 12 – Stockholders’ Equity.

The Company has included the financial results of Advantage Therapy in the consolidated financial statements from August 1, 2018, the date of acquisition.

BioFirma

On August 1, 2018, the Company entered into an agreement to purchase 70% of all outstanding membership units of BioFirma LLC. The purchase price for the interests was $1,000 paid in cash.

The Company has included the financial results of BioFirma in the consolidated financial statements from August 1, 2018, the date of acquisition.

On October 1, 2019, Dr. Ian White and the Company entered into an Assignment and Assumption of Interests of BioFirma LLC, pursuant to which Dr. White assigned to the Company the 30% of BioFirma’s membership interests which were not previously held by the Company, resulting in the Company owning 100% of the membership interests of BioFirma.

On December 31, 2019, the Company and BioFirma consummated the sale of substantially all of BioFirma’s assets pursuant to an asset purchase agreement with Self Care Regeneration LLC for a purchase price of $320,800, plus the assumption of certain of BioFirma’s liabilities, all of which are due to be paid to us no later than March 30, 2020.

IMAC Illinois

On April 1, 2019, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) for the acquisition of a practice management group that manages three clinics in the Chicago, Illinois area. The acquisition was completed on April 19, 2019. Pursuant to the Merger Agreement, the Company issued 1,002,306 restricted shares of the Company’s common stock (the “Merger Consideration”) valued at approximately $4.1 million. The Company has included the financial results of IMAC Illinois from April 19, 2019, the date of acquisition.

The following table summarizes the fair value of consideration paid and the allocation of purchase price to the fair value of net assets acquired for the business acquisitions:

	IMAC Kentucky			IMAC St. Louis		Advantage Therapy			Illinois
Property & equipment	$	607,257		$	-	$	18,647		$	55,693
Intangible assets		4,224,113			264,000		37,000			3,716,285
Goodwill		-			1,327,507		713,189			-
Other assets		5,521			-		255,018			757,388
Current liabilities		(119,902	)		-		(50,948	)		(369,796	)
Noncurrent liabilities		(118,413	)		-		(79,975	)		-
Non-controlling interest		-			-		-			-
	$	4,598,576		$	1,591,507	$	892,931		$	4,159,570

Property and Equipment

12 Months Ended

Dec. 31, 2019

Property, Plant and Equipment [Abstract]

Property and Equipment

Note 7 – Property and Equipment

Property and equipment consisted of the following at December 31:

	Estimated
	Useful Life in Years	2019			2018

Land and building	40	$	1,175,000		$	1,175,000
Leasehold improvements	Shorter of asset or lease term		2,262,398			1,427,828
Equipment	1.5 - 7		1,948,347			1,180,093
Total property and equipment			5,385,745			3,782,921

Less: accumulated depreciation			(1,693,736	)		(449,283	)
Total property and equipment, net		$	3,692,009		$	3,333,638

In March 2018, the Company purchased real estate in Lexington, Kentucky for the development of an IMAC facility for approximately $1.2 million. The Company funded the purchase with a note payable. See Note 11 – Notes Payable.

Depreciation was $748,271 and $383,388 for the years ended December 31, 2019 and 2018, respectively.

Intangibles Assets and Goodwill

12 Months Ended

Dec. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Intangibles Assets and Goodwill

Note 8 – Intangibles Assets and Goodwill

Intangible assets that were acquired in connection with the acquisition transactions (Note 6) during 2018 and 2019:

		December 31, 2018
	Estimated			Accumulated
	Useful Life	Cost		Amortization			Net

Intangible assets:
Management service agreements	10 years	$	4,224,113	$	(211,206	)	$	4,012,907
Non-compete agreements	3 years		301,000		(56,473	)		244,527
Definite lived assets			4,525,113		(267,679	)		4,257,434
Goodwill			2,042,125		-			2,042,125
Total intangible assets and goodwill		$	6,567,238	$	(267,679	)	$	6,299,559

		December 31, 2019
	Estimated			Accumulated
	Useful Life	Cost		Amortization			Net

Intangible assets:
Management service agreements	10 years	$	8,019,199	$	(994,321	)	$	7,024,878
Non-compete agreements	3 years		301,000		(156,806	)		144,194
Definite lived assets			8,320,199		(1,151,127	)		7,169,072
Goodwill			2,040,696		-			2,040,696
Total intangible assets and goodwill		$	10,360,895	$	(1,151,127	)	$	9,209,768

Amortization was $804,648 and $267,679 for the years ended December 31, 2019 and 2018, respectively.

The Company’s estimated future amortization of intangible assets is as follows:

Years Ending December 31,

2020	$	894,373
2021		837,901
2022		794,040
2023		794,040
2024		794,040
Thereafter		3,054,678
	$	7,169,072

Operating Leases

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Operating Leases

Note 9 – Operating Leases

On January 1, 2019, the Company adopted ASC 842 using the modified retrospective method applied to leases that were in place at January 1, 2019. Results for operating periods beginning after January 1, 2019 are presented under ASC 842, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under ASC 840. The Company’s leases consist of operating leases that relate to real estate rental agreements. All of the value of the Company’s lease portfolio relates to real estate lease agreements that were entered into starting March 2017.

Discount Rate Applied to Property Operating Lease

To determine the present value of minimum future lease payments for operating leases at January 1, 2019, the Company was required to estimate a rate of interest that we would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment (the “incremental borrowing rate” or “IBR”).

The Company determined the appropriate IBR by identifying a reference rate and making adjustments that take into consideration financing options and certain lease-specific circumstances. For the reference rate, the Company used the ten year mortgage interest rate.

Right of Use Assets

Right of use assets are included in the consolidated Balance Sheet as follows:

Non-current assets
Right of use assets, net of amortization		$	3,719,401

Total operating lease cost

Individual components of the total lease cost incurred by the Company is as follows:

	December 31, 2019

Operating lease expense	$	1,042,028

Minimum rental payments under operating leases are recognized on a straight light basis over the term of the lease.

Maturity of operating leases

The amount of future minimum lease payments under operating are as follows:

	Operating Leases

Undiscounted future minimum lease payments:
2020	$	1,141,106
2021		945,877
2022		949,333
2023		875,125
2024		536,736
Thereafter		587,955
Total		5,036,132
Amount representing imputed interest		(350,231	)
Total operating lease liability		4,685,901
Current portion of operating lease liability		(1,025,247	)
Operating lease liability, non-current	$	3,660,654

Lines of Credit

12 Months Ended

Dec. 31, 2019

Debt Disclosure [Abstract]

Lines of Credit

Note 10 – Lines of Credit

IMAC Nashville had a $150,000 line of credit with a financial institution that matured on October 15, 2018. The line accrued interest at 6.50% per annum. The line was secured by substantially all of the Company’s assets and personally guaranteed by the members. The line had a $150,000 balance at December 31, 2018 and was repaid in February 2019.

IMAC Kentucky had a $150,000 line of credit with a financial institution that matured on August 1, 2018. The line accrued interest at 4.25% per annum. The line was secured by substantially all of the IMAC Kentucky’s assets and personally guaranteed by the members. The line had a $150,000 balance at December 31, 2018 and was repaid in July 2019.

Advantage Therapy has a $100,000 line of credit with a financial institution that matures on November 20, 2020. The line accrues interest at a variable rate which is currently 6.0% per annum. The line is secured by substantially all of IMAC Holding’s assets. This line of credit had a balance of $79,975 as of December 31, 2019 and 2018.

Progressive had a $750,000 line of credit with a financial institution that matured August 2019. The line had a balance of $140,000 when it was converted to a note payable on September 19, 2019. See Note 11 – Notes Payable for additional information regarding the note payable.

Notes Payable

12 Months Ended

Dec. 31, 2019

Debt Disclosure [Abstract]

Notes Payable

Note 11 – Notes Payable

	December 31,			December 31,
	2019			2018

Note payable to Edward S. Bredniak in the amount of up to $2,000,000. An existing note payable with this entity in the amount of $379,676 has been combined into the new note payable which carries an interest rate of 10% per annum. This note was amended in June 2019 and all outstanding balances are due January 5, 2021.	$	1,750,000		$	1,584,426

Note payable to a financial institution in the amount of $200,000 dated November 15, 2017. The note requires 66 consecutive monthly installments of $2,652 including principal and interest at 5%, with a balloon payment of $60,000 which was paid on June 15, 2018. The note matures on May 15, 2023, and is secured by the personal guarantees of certain Company executives.		99,628			125,670

Convertible notes interest accrued at 4%, convertible to equity at or prior to maturity at a 20% discount to the per share price of a sale of equity securities. At the time of issuance of the convertible notes, the Company was unable to calculate the amount of a beneficial conversion (“BCF”) and related discount to be recorded until the occurrence of a Qualified Financing, which occurred during the first quarter of 2019, at which time the Company recorded the BCF liability and related interest charge of approximately $639,000 associated with the discount. The BCF liability was reclassified to paid-in-capital upon conversion of these convertible notes.		-			1,540,000

$1.2 million six-month mortgage loan with a financial institution with an interest rate of 3.35%. The loan matured in 2019. The principal amount is currently due on demand, with interest being paid monthly.		1,232,500			1,232,500

Note payable to a financial institution in the amount of $131,400 dated August 1, 2016. The note requires 120 monthly installments of $1,394 including principal and interest at 5%. The note matures on July 1, 2026, and is secured by a letter of credit.		93,652			105,374

Note payable to a financial institution in the amount of $200,000 dated May 4, 2016. The note requires 60 monthly installments of $3,881 including principal and interest at 4.25%. The note matures on May 4, 2021, and is secured by the equipment and personal guarantees of certain Company executives.		63,913			106,778

Note payable to an employee in the amount of $101,906 dated March 8, 2017. The note requires payments in five annual installments of $23,350, including principal and interest at 5%. The note matures on December 31, 2021, and is unsecured.		60,000			60,000

Note payable to a financial institution in the amount of $133,555 dated September 17, 2014. The note required 60 monthly installments of $2,475 including principal and interest at 4.25%. The note was repaid in September 2019.		-			21,845

$112,800 payable to a landlord of Advantage Therapy, LLC pursuant to a lease dated March 1, 2019. The debt is payable in 60 monthly installments of $2,129, including principal and interest at 5%. The debt matures on June 1, 2024.		102,744			-

Note payable to a financial institution in the amount of $140,000, dated September 25, 2019. The note requires 36 consecutive monthly installments of $4,225 including principal and interest at 5.39%. The note matures on September 19, 2022 and is secured by a personal guarantee of the Vice President of Business Development of the Company.		129,182			-

		3,531,619			4,776,593
Less: current portion:		(1,422,554	)		(4,459,302	)
	$	2,109,065		$	317,291

Principal maturities of notes payable are as follows:

Years Ending December 31,	Amount

2020	$	1,422,554
2021		1,900,181
2022		104,186
2023		51,657
2024		27,631
Thereafter		25,410
Total	$	3,531,619

Shareholders' Equity

12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Shareholders' Equity

Note 12 – Shareholders’ Equity

Prior to the Company’s conversion to a corporation, the Company had 400 member units authorized with 365 units issued and outstanding.

On June 1, 2018, the Company converted its 365 outstanding member units into 6,582,737 shares of common stock with a $0.001 par value pursuant to the Company’s conversion from a limited liability company to a corporation. The conversion has been given retrospective treatment.

On February 12, 2019, the Company completed a reverse split of its 6,582,737 shares of common stock to 4,533,623 shares of common stock outstanding pursuant to an amendment of the Company’s certificate of incorporation. The reverse split has been given retrospective treatment to December 31, 2017.

During February 2019, the Company completed an initial public offering of securities and issued 850,000 shares of its common stock, along with 1,700,000 warrants to purchase common stock and an option to purchase 34,000 shares of common stock for gross proceeds of $4,356,815. The Company also issued 449,217 shares of common stock for the conversion of its 4% convertible notes and 1,410,183 shares to satisfy deferred acquisition consideration payable in connection with its 2018 business acquisitions.

On April 19, 2019, the Company consummated the transaction contemplated by the Merger Agreement and issued 1,002,306 shares of its common stock as Merger Consideration.

On July 15, 2019, the Company signed a $10 million share purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), an Illinois limited liability company. In consideration for entering into the $10 million agreement, the Company issued to Lincoln Park 60,006 shares of Company common stock as a commitment fee. The Purchase Agreement limits our sales of shares of common stock to Lincoln Park to 1,669,359 shares of common stock, representing 19.99% of the shares of common stock outstanding on the date of the Purchase Agreement unless (a) stockholder approval is obtained to issue more than such amount or (b) the average price of all applicable sales of our common stock to Lincoln Park under the Purchase Agreement equals or exceeds the lower of (i) the closing price of our common stock on the Nasdaq Capital Market immediately preceding July 15, 2019 or (ii) the average of the closing price of our common stock on the Nasdaq Capital Market for the five business days immediately preceding July 15, 2019. As of December 31, 2019, pursuant to the Purchase Agreement, the Company sold an additional 506,454 shares of common stock of the Company to Lincoln Park for aggregate proceeds to the Company of $1,020,224.

2018 Incentive Compensation Plan

The Company’s board of directors and holders of a majority of outstanding shares approved and adopted the Company’s 2018 Incentive Compensation Plan (“2018 Plan”) in May 2018, reserving the issuance of up to 1,000,000 shares of common stock (subject to certain adjustments) upon exercise of stock options and grants of other equity awards. The 2018 Plan provides for the grant of incentive stock options (“ISOs”), nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance-based stock awards, other forms of equity compensation and performance cash awards. ISOs may be granted only to employees. All other awards may be granted to employees, including officers, and to the Company’s non-employee directors and consultants, and affiliates.

Stock Options

At December 31, 2018, the Company had no outstanding stock options to purchase its common stock. During 2019, the Company issued stock options to purchase 292,550 shares of its common stock as non-qualified stock options to various employees of the Company. These options vest over a period of four years, with 25% vesting after one year and the remaining 75% vesting in equal monthly installments over the following 36 months and are exercisable for a period of ten years. Stock based compensation for stock options is estimated at the grant date based on the fair value calculated using the Black-Scholes method. The per-share fair values of these options is calculated based on the Black-Scholes-Merton pricing model with the following assumptions: a volatility rate of 32.2%, risk free rate of 2.4% and the expected term of 10 years.

The information below summarizes the stock options:

	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life
Outstanding at December 31, 2018		-		$	-		-
Granted		310,094			1.86		4.00
Exercised		-			-		-
Cancelled		(17,544	)		1.87		3.53
Outstanding at December 31, 2019		292,550		$	1.85		3.38

Restricted Stock Units

On May 21, 2019, the Company granted an aggregate of 277,500 Restricted Stock Units (“RSUs”) to certain employees, executives and Board members, the terms of which vest over various periods between the date of grant and four years following the date of grant. On August 13, 2019, 30,000 shares of common stock were issued pursuant to granted RSUs which had vested as of such date.

	Number of Shares			Weighted Average Grant Date Fair Value
Outstanding at December 31, 2018		-		$	-
Granted		277,500			4.04
Exercised		-			-
Cancelled		(30,000	)		4.04
Outstanding at December 31, 2019		247,500		$	4.04

Retirement Plan

12 Months Ended

Dec. 31, 2019

Retirement Benefits [Abstract]

Retirement Plan

Note 13 – Retirement Plan

The Company offers a 401(k) plan that covers eligible employees. The plan provides for voluntary salary deferrals for eligible employees. Additionally, the Company is required to make matching contributions of 50% of up to 6 % of total compensation for those employees making salary deferrals. The Company made contributions of $78,768 and $39,115 during 2019 and 2018, respectively.

Income Taxes

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Income Taxes

Note 14 – Income Taxes

The provision for income taxes differs from the amount computed by applying the statutory federal income tax rate to income before provision for income taxes. The sources and tax effects of the differences are as follows:

Deferred tax benefit at the federal statutory rate	21	%
Valuation allowance	-21	%
	0	%

At December 31, 2019, the Company has a net operating loss carryforward of approximately $3.7 million for federal and state purposes. This loss will be available to offset future taxable income. If not used, this carryforward will begin to expire in 2029. The deferred tax asset relating to the operating loss carryforward has been fully reserved at December 31, 2019. The principal differences between the operating loss for income tax purposes and reporting purposes are shares issued for services and share-based compensation and a temporary difference in depreciation expense.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 15 – Commitments and Contingencies

The Company is subject to extensive regulation, including health insurance regulations directed at ascertaining the appropriateness of reimbursement, preventing fraud and abuse and otherwise regulating reimbursement. To ensure compliance, various insurance providers often conduct audits and request patient records and other documents to support claims submitted by the Company for payment of services rendered to customers. In the event that an audit results in discrepancies in the records provided, insurance providers may be entitled to extrapolate the results of the audit to make overpayment demands based on a wider population of claims than those examined in the audit.

From time to time the Company may become subject to threatened and/or asserted claims arising in the ordinary course of our business. Management is not aware of any matters, either individually or in the aggregate, that are reasonably likely to have a material impact on the Company’s financial condition, results of operations or liquidity.

Subsequent Events

12 Months Ended

Dec. 31, 2019

Subsequent Events [Abstract]

Subsequent Events

Note 16 – Subsequent Events

Subsequent to December 31, 2019, pursuant to the Purchase Agreement, the Company sold 771,661 shares of common stock of the Company to Lincoln Park for aggregate proceeds to the Company of $936,660.

On January 13, 2020, the Company consummated an agreement for the acquisition of Chiropractic Health of Southwest Florida, Inc. (CHSF) in Bonita Springs, Florida. The transaction was completed as an all-cash asset purchase for $200,000 and the assumption of building lease liabilities. CHSF, established in 1998, delivers physical therapy, chiropractic care, and soft tissue therapies.

On March 4, 2020, the Company entered into a series of 10% Promissory Notes with two independent directors of the Company, George Hampton and Gerard M. Hayden, Jr., as well as Jeffrey S. Ervin, Chief Executive Officer and director, and Matthew C. Wallis, DC, Chief Operating Officer and director, pursuant to which the Company borrowed a total of $200,000 from these individuals to be used by the Company to fund its working capital requirement. The borrowings under the notes are unsecured and bear interest at a rate of 10% per annum, with interest deferred through and payable on the maturity date of March 25, 2020. The principal amount and interest were repaid by the Company on March 25, 2020.

On March 25, 2020, the Company entered into a note purchase agreement with Iliad Research & Trading, L.P. (the “Holder”), pursuant to which the Company agreed to issue and sell to the Holder a secured promissory note (the “Note”) in an aggregate initial principal amount of $1,115,000 (the “Initial Principal Amount”), which is payable on or before the date that is 18 months from the issuance date (the “Maturity Date”). The Initial Principal Amount includes an original issue discount of $100,000 and $15,000 that the Company agreed to pay to the Holder to cover the Holder’s legal fees, accounting costs, due diligence and other transaction costs. In exchange for the Note, the Holder paid an aggregate purchase price of $1,000,000. Interest on the Note accrues at a rate of 10% per annum and is payable on the Maturity Date or otherwise in accordance with the Note. The Note may be prepaid by the Company (with the payment of a premium), may be required by the Holder to be redeemed by the Company for up to $200,000 per month after the six-month anniversary of the issuance of the Note (subject to certain deferral rights), and is subject to customary events of default (with a default interest rate of up to 22%). The Note transaction documents also give the Holder a right of first refusal to future debt issuances and a right to the first $250,000 of every $1 million of proceeds from future sales of equity by the Company. The Note is secured by the assets of the Company, other than the Company’s owned real property, intellectual property and accounts receivable, pursuant to a security agreement. The Company will use the proceeds of the Note for certain growth initiatives including an IND filing with the FDA.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Principles of Consolidation

Principles of Consolidation

All significant intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

Use of Estimates

Revenue Recognition

Revenue Recognition

The Company’s patient revenue consisted of the following as of December 31, 2019 and 2018:

	2019			2018

Patient revenues	$	32,756,644		$	16,135,967
Contractual adjustments		(17,655,936	)		(9,498,896	)
Patient revenue, net	$	15,100,708		$	6,637,071

Patient Deposits

Patient Deposits

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. The Company had no cash equivalents at December 31, 2019 and 2018.

Accounts Receivable

Accounts Receivable

Allowance for Doubtful Accounts, Contractual and Other Discounts

Allowance for Doubtful Accounts, Contractual and Other Discounts

Property and Equipment

Property and Equipment

Intangible Assets

Intangible Assets

Goodwill

Goodwill

The Company tests goodwill for impairment on an annual basis, or when events or circumstances indicate the fair value of a reporting unit is below its carrying value.

Long-Lived Assets

Long-Lived Assets

Advertising and Marketing

Advertising and Marketing

Net Loss Per Share

Net Loss Per Share

Income Taxes

Income Taxes

Recently Adopted Accounting Pronouncements

Recently Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Schedule of Patient Revenue, Net

The Company’s patient revenue consisted of the following as of December 31, 2019 and 2018:

	2019			2018

Patient revenues	$	32,756,644		$	16,135,967
Contractual adjustments		(17,655,936	)		(9,498,896	)
Patient revenue, net	$	15,100,708		$	6,637,071

Concentration of Credit Risks (Tables)

12 Months Ended

Dec. 31, 2019

Risks and Uncertainties [Abstract]

Schedule of Concentration Risk

As of December 31, 2019 and 2018, the Company had the following revenue and accounts receivable concentrations:

	2019						2018
	% of Revenue			% of Accounts Receivable			% of Revenue			% of Accounts Receivable

Patient payment		47	%		40	%		54	%		54	%
Medicare payment		27	%		26	%		20	%		20	%
Insurance payment		26	%		34	%		26	%		26	%

Accounts Receivable (Tables)

12 Months Ended

Dec. 31, 2019

Receivables [Abstract]

Schedule of Accounts Receivable

Accounts receivable consisted of the following at December 31:

	2019			2018

Accounts receivable, net of contractual adjustments	$	1,285,228		$	314,185
Less: allowance for doubtful accounts		(26,903	)		(10,555	)
Accounts receivable, net	$	1,258,325		$	303,630

Business Acquisitions (Tables)

12 Months Ended

Dec. 31, 2019

Business Combinations [Abstract]

Schedule of Assets Acquired and Liabilities Assumed

The following table summarizes the fair value of consideration paid and the allocation of purchase price to the fair value of net assets acquired for the business acquisitions:

	IMAC Kentucky			IMAC St. Louis		Advantage Therapy			Illinois
Property & equipment	$	607,257		$	-	$	18,647		$	55,693
Intangible assets		4,224,113			264,000		37,000			3,716,285
Goodwill		-			1,327,507		713,189			-
Other assets		5,521			-		255,018			757,388
Current liabilities		(119,902	)		-		(50,948	)		(369,796	)
Noncurrent liabilities		(118,413	)		-		(79,975	)		-
Non-controlling interest		-			-		-			-
	$	4,598,576		$	1,591,507	$	892,931		$	4,159,570

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2019

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment consisted of the following at December 31:

	Estimated
	Useful Life in Years	2019			2018

Land and building	40	$	1,175,000		$	1,175,000
Leasehold improvements	Shorter of asset or lease term		2,262,398			1,427,828
Equipment	1.5 - 7		1,948,347			1,180,093
Total property and equipment			5,385,745			3,782,921

Less: accumulated depreciation			(1,693,736	)		(449,283	)
Total property and equipment, net		$	3,692,009		$	3,333,638

Intangibles Assets and Goodwill (Tables)

12 Months Ended

Dec. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

Intangible assets that were acquired in connection with the acquisition transactions (Note 6) during 2018 and 2019:

		December 31, 2018
	Estimated			Accumulated
	Useful Life	Cost		Amortization			Net

Intangible assets:
Management service agreements	10 years	$	4,224,113	$	(211,206	)	$	4,012,907
Non-compete agreements	3 years		301,000		(56,473	)		244,527
Definite lived assets			4,525,113		(267,679	)		4,257,434
Goodwill			2,042,125		-			2,042,125
Total intangible assets and goodwill		$	6,567,238	$	(267,679	)	$	6,299,559

		December 31, 2019
	Estimated			Accumulated
	Useful Life	Cost		Amortization			Net

Intangible assets:
Management service agreements	10 years	$	8,019,199	$	(994,321	)	$	7,024,878
Non-compete agreements	3 years		301,000		(156,806	)		144,194
Definite lived assets			8,320,199		(1,151,127	)		7,169,072
Goodwill			2,040,696		-			2,040,696
Total intangible assets and goodwill		$	10,360,895	$	(1,151,127	)	$	9,209,768

Schedule of Future Amortization of Intangible Assets

The Company’s estimated future amortization of intangible assets is as follows:

Years Ending December 31,

2020	$	894,373
2021		837,901
2022		794,040
2023		794,040
2024		794,040
Thereafter		3,054,678
	$	7,169,072

Operating Leases (Tables)

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Schedule of Operating Lease Right of Use Assets

Right of use assets are included in the consolidated Balance Sheet as follows:

Non-current assets
Right of use assets, net of amortization		$	3,719,401

Schedule of Operating Lease Cost

Individual components of the total lease cost incurred by the Company is as follows:

	December 31, 2019

Operating lease expense	$	1,042,028

Schedule of Future Minimum Lease Payments

The amount of future minimum lease payments under operating are as follows:

	Operating Leases

Undiscounted future minimum lease payments:
2020	$	1,141,106
2021		945,877
2022		949,333
2023		875,125
2024		536,736
Thereafter		587,955
Total		5,036,132
Amount representing imputed interest		(350,231	)
Total operating lease liability		4,685,901
Current portion of operating lease liability		(1,025,247	)
Operating lease liability, non-current	$	3,660,654

Notes Payable (Tables)

12 Months Ended

Dec. 31, 2019

Debt Disclosure [Abstract]

Schedule of Notes Payable

	December 31,			December 31,
	2019			2018

Note payable to Edward S. Bredniak in the amount of up to $2,000,000. An existing note payable with this entity in the amount of $379,676 has been combined into the new note payable which carries an interest rate of 10% per annum. This note was amended in June 2019 and all outstanding balances are due January 5, 2021.	$	1,750,000		$	1,584,426

Note payable to a financial institution in the amount of $200,000 dated November 15, 2017. The note requires 66 consecutive monthly installments of $2,652 including principal and interest at 5%, with a balloon payment of $60,000 which was paid on June 15, 2018. The note matures on May 15, 2023, and is secured by the personal guarantees of certain Company executives.		99,628			125,670

Convertible notes interest accrued at 4%, convertible to equity at or prior to maturity at a 20% discount to the per share price of a sale of equity securities. At the time of issuance of the convertible notes, the Company was unable to calculate the amount of a beneficial conversion (“BCF”) and related discount to be recorded until the occurrence of a Qualified Financing, which occurred during the first quarter of 2019, at which time the Company recorded the BCF liability and related interest charge of approximately $639,000 associated with the discount. The BCF liability was reclassified to paid-in-capital upon conversion of these convertible notes.		-			1,540,000

$1.2 million six-month mortgage loan with a financial institution with an interest rate of 3.35%. The loan matured in 2019. The principal amount is currently due on demand, with interest being paid monthly.		1,232,500			1,232,500

Note payable to a financial institution in the amount of $131,400 dated August 1, 2016. The note requires 120 monthly installments of $1,394 including principal and interest at 5%. The note matures on July 1, 2026, and is secured by a letter of credit.		93,652			105,374

Note payable to a financial institution in the amount of $200,000 dated May 4, 2016. The note requires 60 monthly installments of $3,881 including principal and interest at 4.25%. The note matures on May 4, 2021, and is secured by the equipment and personal guarantees of certain Company executives.		63,913			106,778

Note payable to an employee in the amount of $101,906 dated March 8, 2017. The note requires payments in five annual installments of $23,350, including principal and interest at 5%. The note matures on December 31, 2021, and is unsecured.		60,000			60,000

Note payable to a financial institution in the amount of $133,555 dated September 17, 2014. The note required 60 monthly installments of $2,475 including principal and interest at 4.25%. The note was repaid in September 2019.		-			21,845

$112,800 payable to a landlord of Advantage Therapy, LLC pursuant to a lease dated March 1, 2019. The debt is payable in 60 monthly installments of $2,129, including principal and interest at 5%. The debt matures on June 1, 2024.		102,744			-

Note payable to a financial institution in the amount of $140,000, dated September 25, 2019. The note requires 36 consecutive monthly installments of $4,225 including principal and interest at 5.39%. The note matures on September 19, 2022 and is secured by a personal guarantee of the Vice President of Business Development of the Company.		129,182			-

		3,531,619			4,776,593
Less: current portion:		(1,422,554	)		(4,459,302	)
	$	2,109,065		$	317,291

Schedule of Principal Maturities of Notes Payable

Principal maturities of notes payable are as follows:

Years Ending December 31,	Amount

2020	$	1,422,554
2021		1,900,181
2022		104,186
2023		51,657
2024		27,631
Thereafter		25,410
Total	$	3,531,619

Shareholders' Equity (Tables)

12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Schedule of Stock Option Activity

The information below summarizes the stock options:

	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life
Outstanding at December 31, 2018		-		$	-		-
Granted		310,094			1.86		4.00
Exercised		-			-		-
Cancelled		(17,544	)		1.87		3.53
Outstanding at December 31, 2019		292,550		$	1.85		3.38

Schedule of Restricted Stock Units

	Number of Shares			Weighted Average Grant Date Fair Value
Outstanding at December 31, 2018		-		$	-
Granted		277,500			4.04
Exercised		-			-
Cancelled		(30,000	)		4.04
Outstanding at December 31, 2019		247,500		$	4.04

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Schedule of Statutory Federal Income Tax Rate

The sources and tax effects of the differences are as follows:

Deferred tax benefit at the federal statutory rate	21	%
Valuation allowance	-21	%
	0	%

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Aug. 31, 2018
Cash equivalents
Impairments of long lived assets
Advertising and marketing expense	1,238,352	859,191
Uncertain tax positions
Advantage Hand Therapy and Orthopedic Rehabilitation, LLC [Member]
Percentage of voting interest acquired			100.00%
BioFirma LLC [Member]
Percentage of voting interest acquired			70.00%

Summary of Significant Accounting Policies - Schedule of Patient Revenue, Net (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Total patient revenue, net	$ 15,100,708	$ 6,637,071
Patient Revenues [Member]
Total patient revenue, net		16,135,967
Contractual Adjustments [Member]
Total patient revenue, net		$ (9,498,896)

Capital Requirements, Liquidity and Going Concern Considerations (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working capital	$ (3,500,000)
Net loss	(6,497,230)	$ (3,053,743)
Net cash (used in) operating activities	$ (4,068,743)	$ (1,808,310)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Concentration of Credit Risks (Details Narrative)	Dec. 31, 2019 USD ($)
Risks and Uncertainties [Abstract]
FDIC insured amount	$ 250,000
Cash and cash equivalents in excess of FDIC	$ 0

Concentration of Credit Risks - Schedule of Concentration Risk (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue [Member] \| Patient Payment [Member]
Concentration of credit risk, percentage	47.00%	54.00%
Revenue [Member] \| Medicare Payment [Member]
Concentration of credit risk, percentage	27.00%	20.00%
Revenue [Member] \| Insurance Payment [Member]
Concentration of credit risk, percentage	26.00%	26.00%
Accounts Receivable [Member] \| Patient Payment [Member]
Concentration of credit risk, percentage	40.00%	54.00%
Accounts Receivable [Member] \| Medicare Payment [Member]
Concentration of credit risk, percentage	26.00%	20.00%
Accounts Receivable [Member] \| Insurance Payment [Member]
Concentration of credit risk, percentage	34.00%	26.00%

Accounts Receivable - Schedule of Accounts Receivable (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Receivables [Abstract]
Accounts receivable, net of contractual adjustments	$ 1,285,228	$ 314,185
Less: allowance for doubtful accounts	(26,903)	(10,555)
Accounts receivable, net	$ 1,258,325	$ 303,630

Business Acquisitions (Details Narrative) - USD ($)			1 Months Ended			12 Months Ended
Business Acquisitions (Details Narrative) - USD ($)	Aug. 02, 2018	Jun. 01, 2018	Apr. 30, 2019	Aug. 31, 2018	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018
Business acquisition, non-controlling interest					$ 300,000
Consideration amount payable in cash							$ 23,931
BioFirma [Member]
Membership interests description						On October 1, 2019, Dr. Ian White and the Company entered into an Assignment and Assumption of Interests of BioFirma LLC, pursuant to which Dr. White assigned to the Company the 30% of BioFirma's membership interests which were not previously held by the Company, resulting in the Company owning 100% of the membership interests of BioFirma.
Self Care Regeneration LLC [Member] \| Asset Purchase Agreement [Member]
Business acquisition, purchase price						$ 320,800
CMA of Kentucky and IMAC St. Louis [Member]
Business acquisition, consideration amount					$ 6,100,000
Advantage Therapy and BioFirma [Member]
Consideration amount payable in cash				$ 900,000
ISDI Holdings II and PHR Holdings [Member]
Consideration amount payable in cash			$ 4,100,000
IMAC St. Louis, LLC [Member]
Business acquisition, consideration amount		$ 1,490,632
Membership interest percentage		64.00%
Ownership percentage		100.00%
IMAC Nashville [Member]
Business acquisition, consideration amount		$ 300,000
Membership interest percentage		25.00%
Advantage Hand Therapy and Orthopedic Rehabilitation, LLC [Member]
Business acquisition, non-controlling interest
Membership interest percentage				100.00%
Estimated purchase price of membership units	$ 892,000
Advantage Hand Therapy and Orthopedic Rehabilitation, LLC [Member] \| Cash [Member]
Estimated purchase price of membership units	22,000
Advantage Hand Therapy and Orthopedic Rehabilitation, LLC [Member] \| Equity [Member]
Estimated purchase price of membership units	$ 870,000
BioFirma LLC [Member]
Membership interest percentage				70.00%
Percentage of outstanding membership units	70.00%
Payments to acquire business gross	$ 1,000
IMAC Management of Progressive, LLC [Member]
Number of restricted stock issued, shares						1,002,306
Number of restricted stock issued, value						$ 4,100,000

Business Acquisitions - Schedule of Assets Acquired and Liabilities Assumed (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2018
Goodwill	$ 2,040,696	$ 2,042,125
Non-controlling interest			$ (300,000)
IMAC Kentucky [Member]
Property & equipment	607,257
Intangible assets	4,224,113
Goodwill
Other assets	5,521
Current liabilities	(119,902)
Noncurrent liabilities	(118,413)
Non-controlling interest
Net Assets Acquired	4,598,576
IMAC St. Louis [Member]
Property & equipment
Intangible assets	264,000
Goodwill	1,327,507
Other assets
Current liabilities
Noncurrent liabilities
Non-controlling interest
Net Assets Acquired	1,591,507
Advantage Hand Therapy and Orthopedic Rehabilitation, LLC [Member]
Property & equipment	18,647
Intangible assets	37,000
Goodwill	713,189
Other assets	255,018
Current liabilities	(50,948)
Noncurrent liabilities	(79,975)
Non-controlling interest
Net Assets Acquired	892,931
Illinois [Member]
Property & equipment	55,693
Intangible assets	3,716,285
Goodwill
Other assets	757,388
Current liabilities	(369,796)
Noncurrent liabilities
Non-controlling interest
Net Assets Acquired	$ 4,159,570

Property and Equipment (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
Property and Equipment (Details Narrative) - USD ($)	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Depreciation		$ 748,271	$ 383,388
Lexington Kentucky [Member]
Payments to acquire real estate	$ 1,200,000

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Total property and equipment, gross	$ 5,385,745	$ 3,782,921
Less: accumulated depreciation	(1,693,736)	(449,283)
Total property and equipment, net	$ 3,692,009	3,333,638
Land and Building [Member]
Estimated Useful Life in Years	40 years
Total property and equipment, gross	$ 1,175,000	1,175,000
Leasehold Improvements [Member]
Estimated Useful Life	Shorter of asset or lease term
Total property and equipment, gross	$ 2,262,398	1,427,828
Equipment [Member]
Total property and equipment, gross	$ 1,948,347	$ 1,180,093
Equipment [Member] \| Minimum [Member]
Estimated Useful Life in Years	1 year 6 months
Equipment [Member] \| Maximum [Member]
Estimated Useful Life in Years	7 years

Intangibles Assets and Goodwill (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 804,648	$ 267,679

Intangibles Assets and Goodwill - Schedule of Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Intangible assets, cost	$ 8,320,199	$ 4,525,113
Intangible assets, Accumulated Amortization	(1,151,127)	(267,679)
Intangible assets, net	7,169,072	4,257,434
Intangible assets, including goodwill, cost	10,360,895	6,567,238
Goodwill	2,040,696	2,042,125
Total intangible assets and goodwill	9,209,768	6,299,559
Definite Lived Assets [Member]
Intangible assets, cost	8,320,199	4,525,113
Intangible assets, Accumulated Amortization	(1,151,127)	(267,679)
Intangible assets, net	$ 7,169,072	$ 4,257,434
Management Service Agreement [Member]
Intangible assets, estimated useful life	10 years	10 years
Intangible assets, cost	$ 8,019,199	$ 4,224,113
Intangible assets, Accumulated Amortization	(994,321)	(211,206)
Intangible assets, net	$ 7,024,878	$ 4,012,907
Non-Compete Agreement [Member]
Intangible assets, estimated useful life	3 years	3 years
Intangible assets, cost	$ 301,000	$ 301,000
Intangible assets, Accumulated Amortization	(156,806)	(56,473)
Intangible assets, net	$ 144,194	$ 244,527

Intangibles Assets and Goodwill - Schedule of Future Amortization of Intangible Assets (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
2020	$ 894,373
2021	837,901
2022	794,040
2023	794,040
2024	794,040
Thereafter	3,054,678
Total	$ 7,169,072	$ 4,257,434

Operating Leases (Details Narrative)	12 Months Ended
Operating Leases (Details Narrative)	Dec. 31, 2019
Leases [Abstract]
Mortgage interest rate term	10 years

Operating Leases - Schedule of Operating Lease Right of Use Assets (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Leases [Abstract]
Right of use assets, net of amortization	$ 3,719,401

Operating Leases - Schedule of Operating Lease Cost (Details)	12 Months Ended
	Dec. 31, 2019 USD ($)
Leases [Abstract]
Operating lease expense	$ 1,042,028

Operating Leases - Schedule of Future Minimum Lease Payments (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Leases [Abstract]
2020	$ 1,141,106
2021	945,877
2022	949,333
2023	875,125
2024	536,736
Thereafter	587,955
Total	5,036,132
Amount representing imputed interest	(350,231)
Total operating lease liability	4,685,901
Current portion of operating lease liability	(1,025,247)
Operating lease liability, non-current	$ 3,660,654

Lines of Credit (Details Narrative) - USD ($)	12 Months Ended
Lines of Credit (Details Narrative) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Line of credit	$ 79,961	$ 379,961
IMAC Nashville, P.C [Member]
Line of credit	$ 150,000
Line of credit, maturity date	Oct. 15, 2018
Line of credit, interest rate	6.50%
Line of credit, repayment date	2019-02
IMAC Nashville, P.C [Member] \| Line of Credit [Member]
Line of credit		150,000
IMAC Kentucky [Member]
Line of credit, maturity date	Aug. 01, 2018
Line of credit, interest rate	4.25%
Line of credit, repayment date	2019-07
IMAC Kentucky [Member] \| Line of Credit [Member]
Line of credit	$ 150,000	150,000
Advantage Theraphy [Member]
Line of credit	$ 100,000
Line of credit, maturity date	Nov. 20, 2020
Line of credit, interest rate	6.00%
Advantage Theraphy [Member] \| Line of Credit [Member]
Line of credit	$ 79,975	$ 79,975
Progressive [Member]
Line of credit	750,000
Progressive [Member] \| Line of Credit [Member]
Line of credit	$ 140,000
Line of credit, maturity date	Aug. 31, 2019

Notes Payable - Schedule of Notes Payable (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Notes payable	$ 3,531,619	$ 4,776,593
Less: current portion	(1,422,554)	(4,459,302)
Notes payable, net of current portion	2,109,065	317,291
Notes Payable [Member]
Notes payable	1,750,000	1,584,426
Notes Payable One [Member]
Notes payable	99,628	125,670
Notes Payable Two [Member]
Notes payable		1,540,000
Notes Payable Three [Member]
Notes payable	1,232,500	1,232,500
Notes Payable Four [Member]
Notes payable	93,652	105,374
Notes Payable Five [Member]
Notes payable	63,913	106,778
Notes Payable Six [Member]
Notes payable	60,000	60,000
Notes Payable Seven [Member]
Notes payable		21,845
Notes Payable Eight [Member]
Notes payable	102,744
Notes Payable Nine [Member]
Notes payable	$ 129,182

Notes Payable - Schedule of Notes Payable (Details) (Parenthetical)								1 Months Ended	12 Months Ended
	Sep. 25, 2019 USD ($) Integer	Mar. 01, 2019 USD ($) Integer	Nov. 15, 2017 USD ($) Integer	Mar. 08, 2017 USD ($) Integer	Aug. 01, 2016 USD ($) Integer	May 04, 2016 USD ($) Integer	Sep. 17, 2014 USD ($) Integer	Jun. 30, 2019	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Jun. 15, 2018 USD ($)
Notes payable									$ 3,531,619	$ 4,776,593
Notes Payable One [Member]
Notes payable			$ 200,000
Debt instrument interest rate			5.00%
Debt instrument maturity date			May 15, 2023
Number of installments \| Integer			66
Debt instrument, periodic payment			$ 2,652
Debt instrument balloon payment											$ 60,000
Notes Payable Two [Member]
Debt instrument interest rate									4.00%
Debt instrument discount, percentage									20.00%
Beneficial conversion feature and interest charge									$ 639,000
Notes Payable Three [Member]
Debt instrument face amount									$ 1,200,000
Debt instrument interest rate									3.35%
Debt instrument maturity date, description									The loan matured in 2019
Notes Payable Four [Member]
Notes payable					$ 131,400
Debt instrument interest rate					5.00%
Debt instrument maturity date					Jul. 01, 2026
Number of installments \| Integer					120
Debt instrument, periodic payment					$ 1,394
Notes Payable Five [Member]
Notes payable						$ 200,000
Debt instrument interest rate						4.25%
Debt instrument maturity date						May 04, 2021
Number of installments \| Integer						60
Debt instrument, periodic payment						$ 3,881
Notes Payable Six [Member]
Notes payable				$ 101,906
Debt instrument interest rate				5.00%
Debt instrument maturity date				Dec. 31, 2021
Number of installments \| Integer				5
Debt instrument, periodic payment				$ 23,350
Notes Payable Seven [Member]
Notes payable							$ 133,555
Debt instrument interest rate							4.25%
Number of installments \| Integer							60
Debt instrument, periodic payment							$ 2,475
Notes Payable Eight [Member]
Notes payable		$ 112,800
Debt instrument interest rate		5.00%
Debt instrument maturity date		Jun. 01, 2024
Number of installments \| Integer		60
Debt instrument, periodic payment		$ 2,129
Notes Payable Nine [Member]
Notes payable	$ 140,000
Debt instrument interest rate	5.39%
Debt instrument maturity date	Sep. 19, 2022
Number of installments \| Integer	36
Debt instrument, periodic payment	$ 4,225
Edward S. Bredniak [Member] \| Notes Payable [Member]
Debt instrument face amount									$ 2,000,000
Notes payable									$ 379,676
Debt instrument interest rate									10.00%
Debt instrument maturity date								Jan. 05, 2021

Notes Payable - Schedule of Principal Maturities of Notes Payable (Details)	Dec. 31, 2019 USD ($)
Debt Disclosure [Abstract]
2020	$ 1,422,554
2021	1,900,181
2022	104,186
2023	51,657
2024	27,631
Thereafter	25,410
Total	$ 3,531,619

Stockholders' Equity (Details Narrative) - USD ($)							1 Months Ended	12 Months Ended
Stockholders' Equity (Details Narrative) - USD ($)	Aug. 13, 2019	Jul. 15, 2019	May 21, 2019	Apr. 19, 2019	Feb. 12, 2019	Jun. 01, 2018	Feb. 28, 2019	Dec. 31, 2019	Dec. 31, 2018	May 31, 2018
Number of units authorized								400
Number of units issued								365
Number of units outstanding								365
Conversion of units into shares, shares						6,582,737
Shares issued price per share						$ 0.001
Reverse split of common stock outstanding					4,533,623
Gross proceeds from initial public offering							$ 4,356,815	$ 3,839,482
Payment in purchase agreement									$ 23,931
Outstanding stock options to purchase stock								310,094
Restricted Stock Units (RSUs) [Member]
Outstanding restricted stock of its common stock			$ 277,500
Number of shares vested	30,000
Non-Qualified Stock Options [Member] \| Various Employees [Member]
Outstanding stock options to purchase stock								292,550
Vesting period								4 years
Vesting percentage								25.00%
Vesting description								These options vest over a period of four years, with 25% vesting after one year and the remaining 75% vesting in equal monthly installments over the following 36 months and are exercisable for a period of ten years. Stock based compensation for stock options is estimated at the grant date based on the fair value calculated using the Black-Scholes method.
Volatility rate								32.20%
Risk free rate								2.40%
Expected term								10 years
2018 Incentive Compensation Plan [Member]
Reserving for issuance										1,000,000
Merger Agreement [Member]
Number of shares issued during period, shares				1,002,306
Purchase Agreement [Member] \| Lincoln Park Capital Fund, LLC [Member]
Payment in purchase agreement		$ 10,000,000
Value of common stock as commitment fee		$ 10,000,000
Number of shares of common stock of commitment fee		60,006
Sale of shares		1,669,359						506,454
Outstanding shares percentage		19.99%
Number of common stock share sold, value								$ 1,020,224
2018 Business Acquisitions [Member]
Stock issued during period, acquisitions							1,410,183
4% Convertible Notes [Member]
Stock issued during period, conversion of securities							449,217
Debt instrument, interest rate							4.00%
Common Stock [Member]
Reverse split of common stock outstanding									(2,049,114)
Number of shares issued during period, shares								596,460
Stock issued during period, conversion of securities								449,217
Stock issued during period, acquisitions								2,412,489
Initial Public Offering [Member] \| Common Stock [Member]
Number of shares issued during period, shares							850,000
Initial Public Offering [Member] \| Warrants to Purchase Common Stock [Member]
Number of shares issued during period, shares							1,700,000
Initial Public Offering [Member] \| Stock Options [Member]
Number of shares issued during period, shares							34,000

Shareholders' Equity - Schedule of Stock Option Activity (Details)	12 Months Ended
	Dec. 31, 2019 $ / shares shares
Equity [Abstract]
Number of Shares Outstanding, beginning balance \| shares
Number of Shares, Granted \| shares	310,094
Number of Shares, Exercised \| shares
Number of Shares, Cancelled \| shares	(17,544)
Number of Shares Outstanding, ending balance \| shares	292,550
Weighted Average Exercise Price Outstanding, beginning balance \| $ / shares
Weighted Average Exercise Price, Granted \| $ / shares	1.86
Weighted Average Exercise Price, Exercised \| $ / shares
Weighted Average Exercise Price, Cancelled \| $ / shares	1.87
Weighted Average Exercise Price Outstanding, ending balance \| $ / shares	$ 1.85
Weighted Average Remaining Contractual Life beginning balance	0 years
Weighted Average Remaining Contractual Life, Granted	4 years
Weighted Average Remaining Contractual Life, Exercised	0 years
Weighted Average Remaining Contractual Life, Cancelled	3 years 6 months 10 days
Weighted Average Remaining Contractual Life ending balance	3 years 4 months 17 days

Shareholders' Equity - Schedule of Restricted Stock Units (Details)	12 Months Ended
	Dec. 31, 2019 $ / shares shares
Equity [Abstract]
Number of Shares Outstanding, beginning balance \| shares
Number of Shares, Granted \| shares	277,500
Number of Shares, Exercised \| shares
Number of Shares, Cancelled \| shares	(30,000)
Number of Shares Outstanding, ending balance \| shares	247,500
Weighted Average Grant Date Fair Value, beginning balance \| $ / shares
Weighted Average Grant Date Fair Value, Granted \| $ / shares	4.04
Weighted Average Grant Date Fair Value, Exercised \| $ / shares
Weighted Average Grant Date Fair Value, Cancelled \| $ / shares	4.04
Weighted Average Grant Date Fair Value, ending balance \| $ / shares	$ 4.04

Retirement Plan (Details Narrative) - 401(k) Plan [Member] - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Matching contributions, percentage of match	50.00%
Matching contributions, percent of employees' gross pay	6.00%
Matching contributions, amount	$ 78,768	$ 39,115

Income Taxes (Details Narrative)	12 Months Ended
Income Taxes (Details Narrative)	Dec. 31, 2019 USD ($)
Income Tax Disclosure [Abstract]
Operating loss carryforward, net	$ 3,700,000
Operating loss carryforward, description	If not used, this carryforward will begin to expire in 2029. The deferred tax asset relating to the operating loss carryforward has been fully reserved at December 31, 2019

Income Taxes - Schedule of Statutory Federal Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Deferred tax benefit at the federal statutory rate	21.00%
Valuation allowance	(21.00%)
Statutory federal income tax rate	0.00%

Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)				3 Months Ended
	Mar. 25, 2020	Mar. 04, 2020	Jan. 13, 2020	Mar. 24, 2020
Series of 10% Promissory Notes [Member] \| Two Independent Directors [Member]
Debt instrument face amount		$ 200,000
Debt interest percentage		10.00%
Debt maturity date		Mar. 25, 2020
Chiropractic Health of Southwest Florida, Inc. [Member]
Asset purchase price			$ 200,000
Purchase Agreement [Member]
Sale of common stock				771,661
Proceeds from sale of common stock				$ 936,660
Purchase Agreement [Member] \| Iliad Research & Trading, L.P. [Member]
Debt instrument face amount	$ 1,115,000
Debt, maturity date description	which is payable on or before the date that is 18 months from the issuance date (the “Maturity Date”)
Original issue discount	$ 100,000
Legal fees, accounting costs, due diligence and other transaction costs	15,000
Aggregate purchase price	$ 1,000,000
Debt instrument, accrued interest percentage.	10.00%
Debt instrument, description of default event	The Note may be prepaid by the Company (with the payment of a premium), may be required by the Holder to be redeemed by the Company for up to $200,000 per month after the six-month anniversary of the issuance of the Note (subject to certain deferral rights), and is subject to customary events of default (with a default interest rate of up to 22%). The Note transaction documents also give the Holder a right of first refusal to future debt issuances and a right to the first $250,000 of every $1 million of proceeds from future sales of equity by the Company. The Note is secured by the assets of the Company, other than the Company's owned real property, intellectual property and accounts receivable, pursuant to a security agreement. The Company will use the proceeds of the Note for certain growth initiatives including an IND filing with the FDA.